The many hurdles of lipid nanoparticle (LNP) scale-up and what to consider
Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines.
But which factors do formulators need to consider when scaling up novel LNP systems? And what hurdles can be expected?
This technical note discusses factors such as flow rates, solvent removal, risks when changing equipment and the impact of tangential flow filtration sensitivity. You can learn what needs to be considered to develop a cost- and time-efficient large-scale process.
